APA (7th ed.) Citation

Chanchlani, N., Lin, S., Auth, M. K., Lee, C. L., Robbins, H., Looi, S., . . . Di Mambro, A. (2022). Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study. Alimentary Pharmacology & Therapeutics, 56(8), 1250. https://doi.org/10.1111/apt.17170

Chicago Style (17th ed.) Citation

Chanchlani, Neil, et al. "Implications for Sequencing of Biologic Therapy and Choice of Second Anti‐TNF in Patients with Inflammatory Bowel Disease: Results from the IMmunogenicity to Second Anti‐TNF Therapy (IMSAT) Therapeutic Drug Monitoring Study." Alimentary Pharmacology & Therapeutics 56, no. 8 (2022): 1250. https://doi.org/10.1111/apt.17170.

MLA (9th ed.) Citation

Chanchlani, Neil, et al. "Implications for Sequencing of Biologic Therapy and Choice of Second Anti‐TNF in Patients with Inflammatory Bowel Disease: Results from the IMmunogenicity to Second Anti‐TNF Therapy (IMSAT) Therapeutic Drug Monitoring Study." Alimentary Pharmacology & Therapeutics, vol. 56, no. 8, 2022, p. 1250, https://doi.org/10.1111/apt.17170.